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Abstract
Background: Vancomycin has recently gained popularity as an empiric therapy for late onset sepsis in the NICU.
Changes in resistance patterns in common organisms has resulted in targeting higher trough concentrations of
vancomycin. Consequently, an increase in vancomycin associated nephrotoxicity has been speculated. The
objective of this study is to compare the incidence of acute kidney injury (AKI) in neonates with serum
vancomycin trough concentrations less than 10 mg/L, 10–15 mg/L, or greater than 15 mg/L.
Methods: A retrospective chart review of patients in the neonatal intensive care unit (NICU) was conducted
to determine the incidence of AKI in neonates receiving vancomycin.
Results: The overall incidence of AKI was 2.7%. Comparison of the incidence of AKI in the three groups
using Mantel-Haenszel Chi-Square test showed a statistically significant association between increasing
vancomycin trough concentration and incidence of AKI.
Conclusion: There is a low incidence of AKI in neonates receiving vancomycin. However, there is a positive
correlation between increasing vancomycin trough concentrations and an increasing serum creatinine.
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Background
Vancomycin is a glycopeptide antibiotic which gained
popularity in 1980’s for treatment of coagulase negative
Staphylococcus (CONS) and Methicillin resistant staphylo-
coccus aureus (MRSA). Late onset sepsis is a common
concern in premature infants in neonatal intensive care
unit (NICU). Vancomycin is widely used as an empiric
therapy for late onset sepsis, and in confirmed infections
with CONS and MRSA. [1, 2] Consequently, vancomycin is
used in the NICU even though limited information is avail-
able concerning the dosing, monitoring, and adverse effects
of this medication in neonates. Additionally, increasing
antibiotic resistance among familiar pathogens in the
NICU, as evidenced by higher minimum inhibitory concen-
trations (MICs), has resulted in targeting higher vanco-
mycin trough concentrations. [3, 4] Vancomycin associated
nephrotoxicity has not been well studied in the neonatal
population and limited data exists on the association
between higher vancomycin trough and incidence of acute
kidney injury (AKI).
This study aims to measure the association between
increasing trough concentrations and AKI in neonates
receiving vancomycin therapy. We also look at the effect
of co-administration of other nephrotoxic agents on the
incidence of AKI.
Methods
A retrospective chart review was performed for patients
in NICU at University of Texas Medical Branch (UTMB)
at Galveston. The electronic medical record was
reviewed between January 2008 and December 2012 to
determine the incidence of AKI in neonates receiving
vancomycin. The patient population consisted of prema-
ture neonates admitted to NICU at UTMB and received
at least one course of vancomycin. Each patient may
have received several courses of vancomycin during this
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period. Courses of vancomycin were included in the
study group if they met the following inclusion criteria:
a) Duration of treatment at least 5 days b) Availability of
serum creatinine (SCr) values both prior to and after
completing the vancomycin therapy and c) at least one
vancomycin trough collected during the duration of
treatment. Courses of vancomycin therapy were ex-
cluded if: a) evidence of pre-existing renal insufficiency
or congenital anomalies including renal agenesis, renal
hypoplasia, polycystic kidney disease, or renal dysplasia
were present b) extracorporeal membrane oxygenation
was required or c) there was incomplete data in the
UTMB electronic medical record, Epic. Baseline serum
creatinine was defined as the serum creatinine obtained
prior to starting vancomycin therapy. Post vancomycin
creatinine was defined as the serum creatinine value
obtained at the end of vancomycin therapy or after a
suspected episode of AKI.
Courses of vancomycin therapy were divided into
three groups based on highest achieved vancomycin
trough concentrations; less than 10 mg/L, 10–15 mg/L,
or greater than 15 mg/L. Standardized vancomycin
dosage proposed by Capparelli et al., based on gesta-
tional age was used for each patient.[5] The trough was
obtained prior to the fourth dose. If the trough was
found sub-therapeutic or toxic, changes in dose or fre-
quency of vancomycin administration were accordingly
made. The change in dose was subsequently followed by
a repeat trough measurement prior to the 4th dose. For
each course of vancomycin therapy, multiple vanco-
mycin trough concentrations may have been measured,
but the highest achieved trough concentration was used
to classify courses of vancomycin therapy into the three
study groups. The incidence of AKI was determined in
each group. AKI was defined as an increase in SCr of at
least 0.5 mg/L or an increase of at least 100% from
lowest trough previously available. This definition is
based on pRIFLE criteria for renal injury proposed by
Akcan-Arikan et al. and the increase in serum creatinine
proposed by moghal et al. [6–8] A decrease in urine out-
put was not used as a defining criteria due to lack of this
being a universal finding.
Data collected included gestational age; postnatal
age; gender; birth weight; APGAR scores; vancomycin
dose, frequency, duration, and trough concentrations;
date and time of vancomycin doses and trough
concentrations; concurrent nephrotoxic medications
administered including amphotericin B, acyclovir, ami-
kacin, captopril, dobutamine, dopamine, enalapril,
epinephrine, ganciclovir, gentamicin, indomethacin,
ibuprofen, naficillin, and tobramycin; blood culture re-
sults; type of infection; presence of a patent ductus
arteriosus; and final discharge status. Maternal history
was also collected and included the presence of
pregnancy-induced hypertension, chorioamnionitis,
diabetes, renal dysfunction, or urinary tract infection.
Mantel-Haenszel Chi-Square test was used to compare
the incidence of AKI between the three groups. A p-
value of < 0.05 was considered to be statistically signifi-
cant. Regression analysis was used to examine the rela-
tionship between vancomycin trough concentrations and
serum creatinine. All statistical analyses were done using
SAS 9.3©. The study was approved by the institutional
review board (IRB) at UTMB, Galveston.
Results
Nine hundred and sixty-two patients receiving vanco-
mycin therapy administered between January 2008 and
December 2012 were evaluated for study inclusion. Eight
hundred and fifty-two patients were excluded due to
inability to meet one or more inclusion criteria. The
majority of patients were excluded due to vancomycin
being administered for less than five days. The second
most common reason for exclusion was incomplete data
in the electronic medical record. Therefore, 110 patients
were included in the analysis. The majority of patients
were male. The mean birth weight was 1200 g, and the
mean gestational age was 29 weeks. (Table 1) Central
line associated blood stream infection (CLABSI), sepsis
and necrotizing enterocolitis (NEC) were the most com-
mon suspected diagnoses for which patients were started
on vancomycin therapy. The most common organism
was Coagulase Negative Staphylococcus aureus (32 pa-
tients) followed by Enterococcus faecalis (5 patients) and
Staphylococcus aureus.
One hundred ten patients were further studied to de-
termine an association with AKI. There were 72 patients
with a highest vancomycin trough concentration less
than 10 mg/L, 27 patients with a highest vancomycin
trough concentration of 10–15 mg/L, and 11 patients
with a highest vancomycin trough concentration greater
than 15 mg/L. The incidence of AKI was 1.39% (1/72
patients) in the group achieving vancomycin trough con-
centrations less than 10 mg/L, 0% (0/27 patients) in the
group achieving vancomycin trough concentrations be-
tween 10–15 mg/L, and 18.18% (2/11 patients) in the
group achieving vancomycin trough concentrations
greater than 15 mg/L (Table 2). There was a statistically
significant association between AKI and vancomycin
trough groups (p = 0.04). Regression analysis between
Table 1 Baseline characteristics of patients
N = 110
Male/Female 58/52
Birth weight (grams) ± SD 1200 ± 734
Gestational age (weeks) ± SD 29 ± 5
Postnatal age at time of first vancomycin course (days) ± SD 23 ± 27
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increasing vancomycin trough concentrations and post
vancomycin serum creatinine values demonstrated a
positive correlation value of 0.32 (p < 0.05) (Fig.1).
Each of the patients with AKI were also receiving at
least one concurrent nephrotoxic medication including
dobutamine, dopamine, and/or gentamicin (Table 3).
Gentamicin was the only nephrotoxic drug that a large
percentage of the 87 patients received during vancomycin
therapy (79%). There was no significant correlation
between post vancomycin creatinine values and the
total number of days’ gentamicin was received (p =
0.10) or of a change in creatinine of greater than or
equal to 0.5 mg/dl from pre- to post-vancomycin
administration (p = 0.13). In an ANOVA regression
equation with gentamicin days run as a covariate with
vancomycin trough group, however, gentamicin days
were significantly associated with post vancomycin
creatinine values (p = 0.04). The vancomycin trough
groups remained significantly associated with post
vancomycin creatinine values independent of gentami-
cin days (p < 0.01).
Discussion
There has been an on-going debate on the dosage, fre-
quency of administration and the most appropriate
monitoring of vancomycin therapy. This is the result of
multiple factors responsible for clearance of vancomycin
including gestational age, post-natal age, weight, renal
tubular function and creatinine levels. [9] Historically,
area-under-the-curve concentration versus time to the
minimum inhibitory concentration (AUC:MIC), was
accepted as the pharmacokinetic and pharmacodynamic
predictor of adequate treatment with vancomycin. AUC:
MIC > 400 has been recommended to achieve desired
anti-microbial effect in both adult and pediatric popula-
tions. [10] A consensus statement released by the
American Society of Health-System Pharmacists, the In-
fectious Diseases Society of America, and the Society of
Infectious Diseases Pharmacists in 2009 recommended
vancomycin as the first choice drug for MRSA with
MIC < 2. [10] The consensus statement also recom-
mends assessment of vancomycin clinical effectiveness
through serum vancomycin trough concentrations at
steady state. Studies have demonstrated that trough
between 7–10 mg/L corresponds to AUC:MIC > 400 if
the MIC of MRSA is < 1. [11] However, with increasing
MIC’s higher trough concentrations are recommended.
In serious clinical infections such as endocarditis, men-
ingitis, hospital-acquired pneumonia, bacteremia, and
osteomyelitis trough concentrations between 15–20 are
recommended.[12] These higher troughs allow for
greater vancomycin exposure, a higher AUC and the
ability to reach the goal AUC:MIC ≥ 400, or a trough
concentration approximately four to five times the MIC
















TOTAL 110 3 2.7%
Fig. 1 Showing a Fit plot between vancomycin trough concentrations and post vancomycin creatinine. The plot depicts a positive co-relation
between the two parameters
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of the infecting organism. [12] Concerns for increased
nephrotoxicity, an adverse effect traditionally associated
with vancomycin, has accompanied the recommendation
for more aggressive dosing.
In adults, increasing serum vancomycin trough concen-
trations have been associated with increasing incidence of
AKI. In a study done to evaluate vancomycin-associated
nephrotoxicity incidence in adults with MRSA infections
with serum trough concentrations of 15–20 mg/L and
receiving concomitant nephrotoxic medications, a signifi-
cantly higher incidence of AKI was noted.[3] A 2011 pro-
spective study also showed similar results. Adults with
MRSA infections had a greater risk of AKI with serum
vancomycin trough concentration greater than 15 mg/
L.[13] Similarly, adults with MRSA pneumonia were
shown to be at a 3–5 times greater risk for developing
AKI with vancomycin serum trough concentrations of
15 mg/L.[14] On the other hand, there are other studies in
adults which did not show increased risk of AKI with
elevated serum vancomycin trough > 15 mg/L. In study
done by Prabaker et al., an overall incidence of 2.1% was
noticed with vancomycin serum trough concentration
between 15–20 mg/L [15].
Nephrotoxicity in the neonatal population is poorly
defined. Several definitions of acute kidney injury (AKI)
exist in the literature; however, there are no standard
criteria for diagnosing AKI in neonates. Commonly used
definitions of AKI in neonates include oliguria of less
than 1 mL/kg/h of urine output that develops 24 h after
birth and persists for at least 24 h, an increase in serum
creatinine (SCr) to greater than 1.5 mg/L 72 h after
birth, or an increase in SCr between 0.5 and 1 mg/L per
day.[8, 16] Nephrotoxicity attributed to vancomycin use
is not clearly defined in neonates; however, the mechanism
of injury to the kidney is believed to be the result of
proximal tubule damage. [17, 18] Although causality
has not been proven, a higher risk of vancomycin-
induced nephrotoxicity in the pediatric population with
higher vancomycin trough concentrations has been
speculated.
Due to pharmacokinetic differences between adults
and neonates, and since neonates have immature renal
function compared to adults, the applicability and
adverse effects of increased target troughs in premature
neonates remain unknown. Lastly, it has been docu-
mented in adult populations that concurrent treatment
using other known nephrotoxic agents, such as amino-
glycosides, is associated with an increased risk for
nephrotoxicity with vancomycin. [19] Again, it is unclear
whether this is true in the neonatal population.
Previously done studies in children receiving vanco-
mycin alone have reported incidence of AKI from 9%–
14%. Linder et al. and Nahata et al. found the incidence
of AKI in neonatal population to be low. Their studies
did not show statistically significant difference in the inci-
dence of AKI with concomitant administration of genta-
micin.[20, 21] However, McKamy and Knoderer et al.
reported slightly higher overall incidence of AKI at 14% in
children between the ages 1 month and 17 years.[17, 22]
Both the studies also reported significantly higher inci-
dence of AKI with vancomycin trough > 15 mg/L at 28%
and 18% respectively.
In our study, the overall incidence of AKI was low at
2.71%. A statistically significant association between AKI
and vancomycin trough groups was found (p = 0.04).
There was also a positive correlation between vanco-
mycin trough concentrations and post vancomycin cre-
atinine values, indicating that vancomycin may have
some role in AKI in predisposed individuals. It also indi-
cates that higher vancomycin troughs are associated with
rising creatinine values post treatment. Additionally, we
looked at several covariates using a linear regression
model to assess whether these were significantly associ-
ated with higher post vancomycin creatinine values. High-
est vancomycin trough value (p < 0.001), total vancomycin
days (p ~ 0.0021) and gestational age (p value < 0.001)
were found to have an independent association. Gender
and APGAR scores were also looked at and were not
found to be significantly associated with vancomycin
trough and rising creatinine values. Even after controlling
for these independent variables, the highest trough value
and post vancomycin creatinine values showed a signifi-
cant association.
Also of interest is the observation that vancomycin
trough groups continued to be positively associated with in-
creasing post vancomycin creatinine values independent of
the number of days of gentamicin the infants had received.
In addition, independent of vancomycin trough groups
there was a positive association between the number of
days that gentamicin was received and post vancomycin
creatinine values. Thus, gentamicin, another potentially
nephrotoxic had its effect on post vancomycin creatinine
Table 3 Cases of acute kidney injury
Case Trough (mg/L) Timing of trough Dose of vancomycin Frequency Duration of treatment Total vancomycin days







2 18.8 Prior to 4th dose 20 mg/kg Q24H 6 days 6 days
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values obscured by the effect of vancomycin. Only after
having the effect of vancomycin controlled for in the re-
gression equation was gentamicin’s effect revealed. Because
of the small number of courses associated with our defin-
ition of acute kidney failure whether or not vancomycin
and gentamicin were additive in their nephrotoxic effects
cannot be determined in this analysis. Larger studies are
needed to confirm these findings.
Our study has limitations. The study was retrospective
in nature and had a small sample size. Due to the lack of
a standardized definition a hybrid definition of AKI was
used in this study. Another limitation is that patients
may have received multiple courses of vancomycin therapy
during the same admission. However, courses of vanco-
mycin therapy were often separated by weeks. Further, for
each course of vancomycin therapy, multiple vancomycin
trough concentrations may have been measured, but the
highest achieved trough concentration was used to divide
the vancomycin courses into the three study groups. Finally,
despite the fact that patients were often on concurrent
nephrotoxic medications, only three cases of AKI were
identified in this study which is different from the previ-
ously reported studies.
Conclusion
Based on our study, vancomycin troughs greater than
20 mg/dl may be associated with increased incidence of
AKI. We recommend close monitoring of vancomycin
trough concentrations during therapy and appropriate
alteration in dosage/frequency should be made based on
serum trough concentrations. However, this was a
single-center retrospective study, and larger prospective
studies are required to validate this finding.
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